Elon's Vision
  • Contacts
  • Privacy Policy
  • Terms & Conditions
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Elon's Vision
No Result
View All Result
Home Investing

GW Pharmaceuticals to build $100m medical cannabis site in Kent

by
March 25, 2022
in Investing
0
GW Pharmaceuticals to build $100m medical cannabis site in Kent
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

The new owner of a British-based pharmaceuticals company that makes cannabis-based treatments is to invest $100 million in a manufacturing facility in Kent.

Jazz Pharmaceuticals, which agreed a $7.2 billion takeover of GW Pharmaceuticals a year ago — understood to be the largest takeover of a UK-based biotech — is to begin construction of the 60,000 sq ft factory at its existing site at Kent Science Park in Sittingbourne.

It is set to create more than 100 “highly skilled” jobs after it opens in 2024 and signals a boost to attempts by the government and industry to rebuild Britain’s drug manufacturing capabilities. Chris Tovey, head of Europe and International at Jazz Pharmaceuticals, said that the investment was “far and away the largest capital investment in the organisation’s history” and would result in more than 500 staff at the site, the largest in the combined group.

GW was founded in 1998 when it secured a licence from the Home Office to grow cannabis in southern England. It floated on the Alternative Investment Market in 2001 before listing on Nasdaq in the United States in 2013.

It made a breakthrough in 2018 when the US Food and Drug Administration approved its lead product, Epidiolex, a cannabis-based treatment for severe childhood epilepsy. The active ingredient used in Epidiolex is cannabidiol, a part of the plant that does not make users high. The site in Kent, formerly owned by Shell, has been occupied by GW since the company’s creation and was chosen because it had a leading research glasshouse. GW’s cannabis is grown commercially at secret locations across the country.

The site manufactures the extract, the active pharmaceutical ingredients and the formulated drug products. Its expansion will increase capacity for Epidiolex and Sativex, its first product, which treats symptoms related to multiple sclerosis. Jazz is seeking to secure approval for Sativex in the US.

The new facility will support the manufacturing of cannabinoid medicines under development from a pipeline that includes nabiximols, which is in phase III trials as a treatment associated with multiple sclerosis. It also has earlier-stage product candidates for other neuroscience disorders, including autism spectrum disorder.

Jazz, which acquired GW last May in a cash and shares deal, is valued at $9.8 billion on Nasdaq and is focused on neuroscience and oncology. It is domiciled in Dublin and has sites across North America and Europe, including in Oxford, Cambridge and London. About a third of Jazz’s 3,000 employees are based in the UK.

The expansion of the Kent site is designed to increase group revenues to $5 billion in 2025 from $3 billion last year. Bruce Cozadd, chairman and chief executive of Jazz, said it would ensure R&D activities were not “crowded out”.

George Freeman, minister for science, research and innovation, said that the investment was a “big sign of confidence in the UK life science ecosystem . . . [and] of UK expertise in cannabinoid science and medicines”. Ministers have expressed a commitment to ensuring that Britain rebuilds its drugs manufacturing infrastructure, following an industry shift towards using offshoring and contract manufacturers, and officials have been given the task of working with the NHS to identify manufacturing requirements.

The group has not received government support as part of the investment but Tovey, 56, said that it was “very reliant on government leaning into everything that it says it’s going to do about continuing to create a really rich talent pool for the technical staff that we require on site”.

GW’s product approvals have helped to attract employees and distinguish the company from “cloudier” parts of the cannabis industry, he said. “What Covid has taught us is that if a medicine is involved it doesn’t matter how desperate things are, people still prefer regulatory-approved medicines.”

Read more:
GW Pharmaceuticals to build $100m medical cannabis site in Kent

Previous Post

Biggest Casino Companies Listed On The Stock Market

Next Post

We must set cryptocurrency rules, admits Bank of England

Next Post
We must set cryptocurrency rules, admits Bank of England

We must set cryptocurrency rules, admits Bank of England

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest

Jay Bhattacharya on Public Health

October 12, 2021

That Bangladesh Mask Study!

December 1, 2021

Antitrust Regulation Assumes Bureaucrats Know the “Correct” Amount of Competition

November 24, 2021
Pints of champagne could be the next ‘Brexit dividend’

Pints of champagne could be the next ‘Brexit dividend’

December 24, 2021

Methodological Individualism in Historical Analysis

0

0

0

0

Methodological Individualism in Historical Analysis

July 5, 2025

Privacy and Fungibility: The Forgotten Virtues of Sound Money

July 5, 2025

Privacy and Fungibility: The Forgotten Virtues of Sound Money

July 5, 2025

Methodological Individualism in Historical Analysis

July 5, 2025

Recent News

Methodological Individualism in Historical Analysis

July 5, 2025

Privacy and Fungibility: The Forgotten Virtues of Sound Money

July 5, 2025

Privacy and Fungibility: The Forgotten Virtues of Sound Money

July 5, 2025

Methodological Individualism in Historical Analysis

July 5, 2025

Disclaimer: ElonsVision.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • Contacts
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 ElonsVision. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 ElonsVision. All Rights Reserved.